In our extended MDS cohort compared to earlier analyses [7] and in line with a skewed apoptotic balance in MDS [12, 13], our gene expression analysis of BIM showed a significantly decreased expression in advanced stages of MDS (MDS-EB-2) when compared to early MDS (MDS-SLD, MDS-MLD, MDS-RS-SLD, MDS-RS-MLD) (p = 0.021) or when compared to intermediate MDS (MDS-EB-1) (p = 0.039) (Figure 1B). Here, BCL2L11 is linked to myelodysplastic syndrome.